Moderna Inc.
Moderna Settles Patent Infringement Litigation with Arbutus/Genevant
Summary
On March 3, 2026, Moderna, Inc. (Moderna) entered into a settlement agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH (Arbutus/Genevant) to resolve all patent infringement litigation pending in the U.S. and internationally. Moderna will make a $950 million noncontingent lump sum payment to Arbutus/Genevant by July 8, 2026. An additional contingent payment of up to $1.3 billion may be due if Moderna does not prevail on its appeal to the Court of Appeals for the Federal Circuit regarding the applicability of 28 U.S.C. § 1498 to the litigation. The Settlement Agreement also includes a fully paid-up, royalty-free, worldwide license for Moderna to use certain Arbutus/Genevant patents related to its infectious disease vaccines and a covenant not to sue. This settlement provides certainty for Moderna's full infectious disease portfolio, including future vaccine pipeline.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement